A Phase 2 Study to Evaluate the Safety and Efficacy of BEY2153 in Patients with Early Alzheimer's Disease
Phase 2
Not yet recruiting
- Conditions
- Alzheimer DiseaseAlzheimer' Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-03-20
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- BeyondBio Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT06885567
- Locations
- π°π·
Severance Hospital, Seoul, Korea, Republic of
π°π·SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of
π°π·Yeouido St. Mary's Hospital, Seoul, Korea, Republic of
A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM)
Phase 1
Recruiting
- Conditions
- Glioblastoma Multiforme
- Interventions
- Combination Product: Temozolomide
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- BeyondBio Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05769660
- Locations
- π°π·
Seoul National University Hospital, Seoul, Korea, Republic of
A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer
Phase 1
Recruiting
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Combination Product: Capecitabine
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- BeyondBio Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT05093907
- Locations
- π°π·
Seoul National University Hospial, Seoul, Jongro-go, Korea, Republic of
A Study to Evaluate the Pharmacokinetics and Safety of BEY2153 in Healthy Participants
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- BeyondBio Inc.
- Target Recruit Count
- 88
- Registration Number
- NCT04476303
- Locations
- π°π·
Seoul National University Hospital, Seoul, Korea, Republic of
Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer
Phase 1
Recruiting
- Conditions
- Locally Advanced or Metastatic Pancreatic Cancer
- Interventions
- Combination Product: Gemcitabine
- First Posted Date
- 2018-07-09
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- BeyondBio Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT03579836
- Locations
- π°π·
Yonsei University Health System Severance Hospital, Seoul, Korea, Republic of
Β© Copyright 2025. All Rights Reserved by MedPath